House Committee Calls On EPO Marketers To Provide Information, Halt DTC Ads
This article was originally published in The Pink Sheet Daily
Executive Summary
Inquiry also requests Amgen and Johnson & Johnson cease financial incentives to physicians.
You may also be interested in...
EPO Aggressive Dosing May Be Curtailed By New Black Box Warning
Labeling for Amgen’s Aranesp and Epogen and Johnson & Johnson’s Procrit updated March 9 to include a black box warning on risk of mortality.
Boxed Warning In Development For Procrit, Aranesp
Erythropoietin marketers J&J and Amgen will participate in an FDA Oncologic Drugs Advisory Committee meeting in May.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.